Galectin Therapeutics (formerly known as Pro-Pharmaceuticals) has a knack for inhibiting galectin proteins. The drug developer is targeting galectin proteins as they play a key role in the development of a variety of diseases. It is developing such inhibitors to treat liver fibrosis, which is currently untreatable. Its GM-CT-01 drug candidate is being investigated for use targeting certain melanomas and in combination with another drug to improve its effectiveness in treating colorectal cancer.